RxTrials Institute Drug Pipeline Alert

The study is an open-label, single-center, single-arm, dose-escalating trial of romidepsin in combination with Velcade (bortezomib) and dexamethasone followed by maintenance romidepsin therapy until disease progression. Patients who received the combination had an overall response rate of 85 percent, Gloucester said.

Romidepsin is being investigated as a treatment for hematologic malignancies. “While romidepsin has demonstrated significant single-agent activity in other difficult to treat cancers, the high response rates observed in this combination study in a relapsed or refractory patient population are very exciting,” the company said in a statement.